With an acceleration in sales momentum in Q3 17 relative to the first half (Q3: +22.6%; Q2: +18.5%; Q1: +19.1%), Ipsen remains on track to achieve its revenue and profitability guidance for FY17. However, with mounting competition in NET, botulinum toxin and the first-line RCC marketplace, the company will need to work hard to maintain its trajectory of market share gain in the mid-term.
04 Jan 2018
Decent set of results; competition to intensify in the mid-term
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Decent set of results; competition to intensify in the mid-term
Ipsen SA (IPN:WBO) | 0 0 5.0% | Mkt Cap: 10,144m
- Published:
04 Jan 2018 -
Author:
Sumit Sayal -
Pages:
4
With an acceleration in sales momentum in Q3 17 relative to the first half (Q3: +22.6%; Q2: +18.5%; Q1: +19.1%), Ipsen remains on track to achieve its revenue and profitability guidance for FY17. However, with mounting competition in NET, botulinum toxin and the first-line RCC marketplace, the company will need to work hard to maintain its trajectory of market share gain in the mid-term.